Market Overview

ARADIGM INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 in Aradigm Corporation to Contact the Firm

Share:

Faruqi & Faruqi, LLP, a leading national securities law firm, reminds
investors in Aradigm Corporation ("Aradigm" or the "Company")
(NASDAQ:ARDM) of the March 12, 2018 deadline to seek the role of lead
plaintiff in a federal securities class action that has been filed
against the Company.

If you invested in Aradigm stock or options between July 27, 2017 and
January 8, 2018
and would like to discuss your legal rights, click
here
: www.faruqilaw.com/ARDM.
There is no cost or obligation to you.

You can also contact us by calling Richard Gonnello toll free at
877-247-4292
or at 212-983-9330 or by sending an e-mail to rgonnello@faruqilaw.com.

The lawsuit has been filed in the U.S. District Court for the Northern
District of California on behalf of all those who purchased Aradigm
common stock between July 27, 2017 and January 8, 2018 (the "Class
Period"). The case, Kheder v. Aradigm Corporation et al, No.
18-cv-00261 was filed on January 11, 2018.

The lawsuit focuses on whether the Company and its executives violated
federal securities laws by making false and/or misleading statements
and/or failing to disclose that: (i) the methodology underlying
Aradigm's Linhaliq Phase III clinical trials was not well tailored to
yield consistent efficacy findings or to provide data sufficient to
account for discordant efficacy findings; (ii) the endpoint of the Phase
III trials—namely, delaying the time to first exacerbation on study
therapy compared to placebo over approximately one year of
observation—was unlikely to demonstrate a clinically meaningful benefit
with respect to a patient population that would likely be taking the
drug for a longer duration; (iii) accordingly, these studies were
unlikely to support Food and Drug Administration's ("FDA") approval of
the Linhaliq New Drug Application ("NDA"); and (iv) as a result,
Aradigm's public statements were materially false and misleading at all
relevant times.

Specifically, on January 9, 2017, the FDA published briefing documents
for the meeting with the Antimicrobial Drugs Advisory Committee on its
website stating, in part, that "[r]easons for the discordance in
efficacy findings between trials cannot be explained based on the
information collected in the two trials." The FDA also expressed concern
as to whether longer exposure to Linhaliq's active agent, ciprofloxacin,
"as would be expected in clinical practice (likely lifelong after
starting therapy), would result in additional safety issues and
bacterial resistance leading to erosion of efficacy over time."

On this news, Aradigm's share price fell from $5.98 per share on January
8, 2018 to a closing price of $3.70 on January 9, 2018 — a $2.28 or a
38.13% drop.

The court-appointed lead plaintiff is the investor with the largest
financial interest in the relief sought by the class who is adequate and
typical of class members who directs and oversees the litigation on
behalf of the putative class. Any member of the putative class may move
the Court to serve as lead plaintiff through counsel of their choice, or
may choose to do nothing and remain an absent class member. Your ability
to share in any recovery is not affected by the decision to serve as a
lead plaintiff or not.

Faruqi & Faruqi, LLP also encourages anyone with information regarding
Aradigm's conduct to contact the firm, including whistleblowers, former
employees, shareholders and others.

Attorney Advertising. The law firm responsible for this advertisement is
Faruqi & Faruqi, LLP (www.faruqilaw.com).
Prior results do not guarantee or predict a similar outcome with respect
to any future matter. We welcome the opportunity to discuss your
particular case. All communications will be treated in a confidential
manner.

View Comments and Join the Discussion!